Cargando…

Efficacy and safety of livwin (polyherbal formulation) in patients with acute viral hepatitis: A randomized double-blind placebo-controlled clinical trial

OBJECTIVES: The study was planned to evaluate the efficacy and safety of Livwin (polyherbal formulation) in acute viral hepatitis. MATERIALS AND METHODS: In this study, there were 29 patients in each group, receiving either Livwin (containing Ashwagandha, Arjuna, Bhumyamalaki, Daruharidra, Guduchi,...

Descripción completa

Detalles Bibliográficos
Autores principales: Keche, Yogendra, Badar, Vandana, Hardas, Mrunalini
Formato: Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059443/
https://www.ncbi.nlm.nih.gov/pubmed/21455448
http://dx.doi.org/10.4103/0974-7788.76784
_version_ 1782200406837821440
author Keche, Yogendra
Badar, Vandana
Hardas, Mrunalini
author_facet Keche, Yogendra
Badar, Vandana
Hardas, Mrunalini
author_sort Keche, Yogendra
collection PubMed
description OBJECTIVES: The study was planned to evaluate the efficacy and safety of Livwin (polyherbal formulation) in acute viral hepatitis. MATERIALS AND METHODS: In this study, there were 29 patients in each group, receiving either Livwin (containing Ashwagandha, Arjuna, Bhumyamalaki, Daruharidra, Guduchi, Kutki and Punarnava) or placebo capsules containing lactose powder (500 mg). Both drugs were given orally two capsules two times a day for eight weeks followed by treatment free period of four weeks. Recovery of patients was assessed by noting symptomatic recovery and by measuring levels of serum bilirubin, serum aspartate aminotransferase (AST), serum alanine aminotransferase (ALT), alkaline phosphatase at baseline, 2, 4, 8 and 12 weeks. RESULTS: Significant earlier recovery of weakness was observed with Livwin as compared to placebo at 2, 4 and 8 weeks. Serum bilirubin and ALT was observed in normal range in significantly more number of patients with Livwin treatment as compared to placebo at 2, 4 and 8 weeks. AST was observed in normal range in significantly more number of patients with Livwin treatment as compared to placebo at 2 and 4 weeks. CONCLUSIONS: Livwin is found effective in uncomplicated patients of acute viral hepatitis. Epigastric pain and diarrhea were reported with Livwin treatment.
format Text
id pubmed-3059443
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-30594432011-03-31 Efficacy and safety of livwin (polyherbal formulation) in patients with acute viral hepatitis: A randomized double-blind placebo-controlled clinical trial Keche, Yogendra Badar, Vandana Hardas, Mrunalini Int J Ayurveda Res Original Article OBJECTIVES: The study was planned to evaluate the efficacy and safety of Livwin (polyherbal formulation) in acute viral hepatitis. MATERIALS AND METHODS: In this study, there were 29 patients in each group, receiving either Livwin (containing Ashwagandha, Arjuna, Bhumyamalaki, Daruharidra, Guduchi, Kutki and Punarnava) or placebo capsules containing lactose powder (500 mg). Both drugs were given orally two capsules two times a day for eight weeks followed by treatment free period of four weeks. Recovery of patients was assessed by noting symptomatic recovery and by measuring levels of serum bilirubin, serum aspartate aminotransferase (AST), serum alanine aminotransferase (ALT), alkaline phosphatase at baseline, 2, 4, 8 and 12 weeks. RESULTS: Significant earlier recovery of weakness was observed with Livwin as compared to placebo at 2, 4 and 8 weeks. Serum bilirubin and ALT was observed in normal range in significantly more number of patients with Livwin treatment as compared to placebo at 2, 4 and 8 weeks. AST was observed in normal range in significantly more number of patients with Livwin treatment as compared to placebo at 2 and 4 weeks. CONCLUSIONS: Livwin is found effective in uncomplicated patients of acute viral hepatitis. Epigastric pain and diarrhea were reported with Livwin treatment. Medknow Publications & Media Pvt Ltd 2010 /pmc/articles/PMC3059443/ /pubmed/21455448 http://dx.doi.org/10.4103/0974-7788.76784 Text en Copyright: © International Journal of Ayurveda Research http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Keche, Yogendra
Badar, Vandana
Hardas, Mrunalini
Efficacy and safety of livwin (polyherbal formulation) in patients with acute viral hepatitis: A randomized double-blind placebo-controlled clinical trial
title Efficacy and safety of livwin (polyherbal formulation) in patients with acute viral hepatitis: A randomized double-blind placebo-controlled clinical trial
title_full Efficacy and safety of livwin (polyherbal formulation) in patients with acute viral hepatitis: A randomized double-blind placebo-controlled clinical trial
title_fullStr Efficacy and safety of livwin (polyherbal formulation) in patients with acute viral hepatitis: A randomized double-blind placebo-controlled clinical trial
title_full_unstemmed Efficacy and safety of livwin (polyherbal formulation) in patients with acute viral hepatitis: A randomized double-blind placebo-controlled clinical trial
title_short Efficacy and safety of livwin (polyherbal formulation) in patients with acute viral hepatitis: A randomized double-blind placebo-controlled clinical trial
title_sort efficacy and safety of livwin (polyherbal formulation) in patients with acute viral hepatitis: a randomized double-blind placebo-controlled clinical trial
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059443/
https://www.ncbi.nlm.nih.gov/pubmed/21455448
http://dx.doi.org/10.4103/0974-7788.76784
work_keys_str_mv AT kecheyogendra efficacyandsafetyoflivwinpolyherbalformulationinpatientswithacuteviralhepatitisarandomizeddoubleblindplacebocontrolledclinicaltrial
AT badarvandana efficacyandsafetyoflivwinpolyherbalformulationinpatientswithacuteviralhepatitisarandomizeddoubleblindplacebocontrolledclinicaltrial
AT hardasmrunalini efficacyandsafetyoflivwinpolyherbalformulationinpatientswithacuteviralhepatitisarandomizeddoubleblindplacebocontrolledclinicaltrial